| Name | Title | Contact Details |
|---|
Tremont Strategies Group is a full service government affairs consulting firm offering a wide range of practices and committed to offering the highest quality service to its clients. Our firm specializes in executing complex, multi-faceted campaigns by utilizing a comprehensive approach to engage stakeholders, policymakers and the general public in order to educate and advocate for our client`s position. With decades of experience in the public and private sectors, we offer in-depth analysis on policy matters and proposals before state and federal government. Our team provides the expertise and entrepreneurial creativity needed to build successful comprehensive public affairs strategies.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Invio Automation is a prominent provider of custom automation solutions, focusing on designing, building, and integrating advanced systems for high-growth industries. The company serves sectors such as Medical Device & Life Sciences, Renewable Energy, Mobility, Logistics & Fulfillment, and Industrial. With over 65 years of experience, Invio is headquartered in Hudson, NH, and operates seven production sites across North America. The team at Invio consists of hundreds of engineers and skilled professionals dedicated to delivering large-scale automation projects. Their offerings include robotic automation services, development of Autonomous Mobile Robots (AMRs), and a range of specialized solutions such as thermal bonding and precision dispensing. Invio also provides consulting and R&D services to help clients prepare for future automation needs. The company collaborates with a diverse customer base, supporting operations of all sizes across various industries.